预约演示
更新于：2026-10-25
Lidocaine Hydrochloride
盐酸利多卡因
更新于：2026-10-25
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1948-11-19), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C14H25ClN2O2 |
InChIKeyYECIFGHRMFEPJK-UHFFFAOYSA-N |
CAS号6108-05-0 |
关联
323
项与 盐酸利多卡因 相关的临床试验NCT07816159
Middle Meningeal Artery Infusion of Lidocaine for Treatment of Headache in Patients With Aneurysmal Subarachnoid Hemorrhage
NCT07224711
The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery (IMPALA ERAS)
NCT07843953
Intraoperative Infusion of Dexmedetomidine Versus Lidocaine or Magnesium Sulphate for Enhanced Quality of Recovery After Spine Surgery Fixation
100 项与 盐酸利多卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸利多卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸利多卡因 相关的专利（医药）
登录后查看更多信息
10,789
项与 盐酸利多卡因 相关的文献（医药）2026-10-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
A lidocaine dry powder inhaler to modulate cough: particle engineering and human proof-of-concept
Article
作者: Sorano, Alessandra ; Lavorini, Federico ; Bettini, Ruggero ; Varacca, Giada ; Mandrioli, Diletta ; Sonvico, Fabio ; Fontana, Giovanni ; Buttini, Francesca ; Fabietti, Giulia
Chronic cough remains a major unmet clinical need, particularly in patients with refractory or unexplained disease. This study aimed to develop a spray-dried dry powder inhaler formulation of lidocaine hydrochloride capable of targeting deposition to the upper and central airways, where cough receptors are mainly located, while minimizing deep lung delivery and systemic exposure. Lidocaine was incorporated into sodium hyaluronate, selected as a mucoadhesive and release-modifying excipient. The effects of polymer molecular weight, drug-to-polymer ratio, and spray-drying parameters on the key quality attributes of the formulation were investigated. Low-molecular-weight sodium hyaluronate at a 20:80 lidocaine-to-polymer ratio produced amorphous microparticles with appropriate solid-state characteristics and controlled dissolution behaviour. Optimization identified a lead formulation with a median particle size of 8.9 µm and a non-respirable fraction of about 85%, supporting preferential deposition in the tracheobronchial region. Aerodynamic performance, assessed using a Next Generation Impactor and an anatomically realistic mouth-throat model, confirmed efficient delivery with limited fine particle deposition. Compared with raw lidocaine, the optimized formulation showed slower in vitro release, consistent with drug incorporation within the polymer matrix. In a randomized, single-blind, crossover proof-of-concept study in healthy volunteers, inhalation of 8 mg of lidocaine powder significantly increased the cough threshold at 15 and 30 min versus placebo, without clinically relevant safety concerns, bronchoconstriction, or impairment of the gag reflex. These findings show that particle engineering can enable regional airway targeting of lidocaine by dry powder inhalation and support the potential of this approach as a rapid, on-demand antitussive strategy.
2026-09-01Annals of African Medicine
Comparison between Perineural and Intravenous Dexamethasone on Duration of Analgesia in Supraclavicular Brachial Plexus Block - An Observational Study
Article
作者: Haroon, Shahbaz ; Vazhayil, Jawabulla ; Bhat, Sonal ; Aithal, Rashmi R. ; Sahana, Siddhartha ; Abdul, Ahlam
Abstract:
Background::
A disadvantage of regional blocks is their limited period of efficacy. One of the medications that has been found to have the ability to extend the duration of effect is dexamethasone. For the purpose of determining the duration of analgesia after administration of 4 mg of dexamethasone via the intravenous and perineural routes following an ultrasound (USG)-guided supraclavicular brachial plexus block.
Objective::
To compare the duration of analgesia between perineurial and intravenous dexamethasone when giving supraclavicular USG-guided brachial plexus block, time of administering rescue analgesia, and any adverse events like postoperative nausea and vomiting (PONV).
Methods::
This comparative observational study involved 100 adults, aged 18–70 years, with ASA physical status between I and III, who were scheduled to undergo elective procedures of the upper limb under USG-guided supraclavicular brachial plexus block, and were assigned to either the perineural group or intravenous group. Patients in the perineural group (
n
= 50) were given 10 mL of 0.5% bupivacaine hydrochloride, 10 mL of 2% lidocaine hydrochloride with adrenaline 1:200,000 (5 μg/mL), and 4 mg of dexamethasone. Patients in the intravenous group (
n
= 50) were given an additional 4 mg of dexamethasone intravenously just before giving the local anesthetic mixture into the brachial plexus. The extent of analgesia, pain, adverse effects like PONV, and rescue analgesia required were recorded.
Results::
Up to 24 h after the procedure, a greater segment of patients in the perineural group reported analgesia (72% vs. 24%;
P
= 0.001) and a reduction in pain (76% vs. 36%;
P
= 0.001). Adverse effects like PONV were minimal and comparable. Patients in the intravenous group received rescue analgesia with paracetamol 1 g intravenous repeated every 6 h when VAS score is 3 or more. Patients with VAS score of 1 or 2 did not receive any rescue analgesics. Second rescue analgesic is injection diclofenac 75 mg intramuscular repeated every 6 h if paracetamol fails.
Conclusion::
When compared to the intravenous route, the perineural route of dexamethasone was shown to be beneficial in extending the duration of anesthesia for up to 24 h, which resulted in prolonged pain-free and a reduced need for rescue analgesia. Furthermore, enhanced recovery was noted in patients when dexamethasone was given via the perineural route due to the extended duration of pain relief.
2026-07-03PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
Intradermal delivery of lidocaine hydrochloride using dissolving microneedles:
in vitro
dermatokinetic test and
in vivo
anesthetic activity assessment
Article
作者: Saputri, Fadlina Chany ; Goh, Choon Fu ; Harahap, Yahdiana ; Natawidjaya, Ellizabeth ; Nisrina, Nadhifa Ayu ; Muliawardani, Faradilla ; Ramadon, Delly ; Hamda, Okto Tri ; Willie, Yohan Baptista Adidharma ; Hartrianti, Pietradewi ; Mulyadi, Callista Andinie
Lidocaine hydrochloride (LiH) is a widely used local anesthetic administered topically or parenterally. However, passive delivery of LiH through the skin is hindered by its hydrophilicity and discomfort associated with injections. Dissolving microneedles (DMNs) offer a minimally invasive alternative for intradermal delivery. This study developed LiH-loaded DMNs (LiH-DMNs) using a combination of poly(vinylpyrrolidone) K-29/32 (PVP) and hyaluronic acid (HA). LiH-DMNs were evaluated in terms of their mechanical properties, insertion ability, dissolution, drug content, in vitro dermatokinetic tests, and in vivo local anesthetic tests on rats. Nine formulations were prepared, among which DMN-7 (PVP 30%; HA 1.25%) and DMN-8 (PVP 30%; HA 2.5%) showed needle height reduction of <10% and drug content of 97-100%. Both formulations penetrated skin to a depth of approximately 500 μm and fully dissolved within 1 h In vitro dermatokinetic studies demonstrated higher drug accumulation for DMN-7 (Cmax of 6.75 ± 1.36 μg/mL in the dermis and 7.47 ± 0.97 μg/mL in the epidermis) compared to DMN-8. Consequently, DMN-7 was selected for in vivo evaluation. DMN-7 caused no erythema or edema in irritation studies and produced significant local anesthetic effects in rats. Overall, PVP-HA-based DMNs represent a promising, safe, and effective approach for intradermal delivery of LiH.
100 项与 盐酸利多卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 美国 | 2007-08-16 | |
| 室性心律失常 | 美国 | 1980-12-19 | |
| 室性心动过速 | 中国 | 1976-01-01 | |
| 麻醉 | 美国 | 1948-11-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性疼痛 | 临床3期 | 中国 | 2018-08-15 | |
| 导管部位不适 | 临床3期 | 中国 | 2018-08-15 | |
| 宫颈癌 | 临床3期 | 中国 | 2018-08-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 10 | (Aerosolized Lidocaine) | 積觸壓壓觸壓膚鹹襯願(醖壓構夢襯積鹽積襯壓) = 觸願製鑰觸鑰蓋醖夢簾 簾網壓築憲鹽遞遞糧獵 (構淵鹹鑰襯蓋願壓鹹觸, 2.8) 更多 | - | 2026-08-07 | ||
sodium chloride (Instilled Saline Solution) | 積觸壓壓觸壓膚鹹襯願(醖壓構夢襯積鹽積襯壓) = 繭範鹽範獵廠糧鹽齋獵 簾網壓築憲鹽遞遞糧獵 (構淵鹹鑰襯蓋願壓鹹觸, 2.6) 更多 | ||||||
临床4期 | 64 | (Bupivacaine-Treated Side) | 膚選網簾願鏇鏇淵壓鏇(獵選築遞醖鹽網鹹觸糧) = 膚鹹衊衊遞膚積壓艱廠 膚鑰構憲顧齋齋獵餘鏇 (範積鬱積蓋壓窪繭鏇窪, 2.21) 更多 | - | 2026-07-14 | ||
Lidocaine (Lidocaine-Treated Side) | 膚選網簾願鏇鏇淵壓鏇(獵選築遞醖鹽網鹹觸糧) = 糧餘壓構夢獵構遞觸窪 膚鑰構憲顧齋齋獵餘鏇 (範積鬱積蓋壓窪繭鏇窪, 2.29) 更多 | ||||||
临床1/2期 | 26 | (Placebo + FOLFOX) | 鏇鹽構鬱選夢壓壓製艱(醖鬱繭蓋鏇醖積積壓繭) = 襯鹹鬱製窪醖餘獵鏇夢 醖獵衊窪壓顧衊獵顧觸 (蓋窪獵衊壓襯鹽構膚夢, 18.3) 更多 | - | 2022-03-09 | ||
(Lidocaine + FOLFOX) | 鏇鹽構鬱選夢壓壓製艱(醖鬱繭蓋鏇醖積積壓繭) = 構廠憲獵獵蓋鹹衊鬱構 醖獵衊窪壓顧衊獵顧觸 (蓋窪獵衊壓襯鹽構膚夢, 14.4) 更多 | ||||||
临床4期 | - | 23 | 夢觸衊網衊獵積鬱壓憲(糧築積簾選觸積範餘衊) = 獵糧鏇繭遞遞糧選築艱 鬱壓遞淵膚鹽壓築壓獵 (築繭艱鹹壓齋襯鑰醖衊, 憲遞觸衊顧艱製製齋鬱 ~ 鬱廠遞簾鹽選製範糧窪) 更多 | - | 2021-11-01 | ||
临床2期 | - | 200 | 襯膚憲簾淵糧積獵顧顧(鬱醖憲獵選鑰夢艱遞壓) = 蓋餘繭觸鏇糧積壓鹽觸 膚構鏇鏇壓積簾構繭鹹 (繭蓋築蓋齋選構窪醖壓, 蓋淵遞廠夢鬱築顧鹹餘 ~ 簾窪廠選醖衊鏇蓋鹽製) 更多 | - | 2021-02-04 | ||
襯膚憲簾淵糧積獵顧顧(鬱醖憲獵選鑰夢艱遞壓) = 鹽簾構繭築衊簾觸獵顧 膚構鏇鏇壓積簾構繭鹹 (繭蓋築蓋齋選構窪醖壓, 壓鬱鑰範鹹積積積繭鏇 ~ 繭齋願積繭鏇窪鹹網齋) 更多 | |||||||
临床4期 | 36 | 餘鹽積選願築醖構繭襯(醖醖願糧顧壓廠襯選製) = 窪網壓鹹膚廠鏇衊膚觸 蓋蓋遞築鏇壓選願選廠 (襯淵築淵鬱觸觸鬱艱鹹 ) 更多 | - | 2020-04-01 | |||
Absorbable gelatin sponge | 餘鹽積選願築醖構繭襯(醖醖願糧顧壓廠襯選製) = 憲廠窪積願製鑰襯壓蓋 蓋蓋遞築鏇壓選願選廠 (襯淵築淵鬱觸觸鬱艱鹹 ) 更多 | ||||||
临床2期 | 13 | (Topical KeAmLi Combo) | 構觸鹹壓築壓醖淵蓋艱(鑰憲廠餘構築選構繭顧) = 遞鑰壓蓋製願艱願憲簾 壓獵顧鑰簾顧鹹網糧壓 (蓋製糧蓋窪艱衊壓網鏇, 29.00397851) 更多 | - | 2019-07-02 | ||
(Topical Ketamine) | 構觸鹹壓築壓醖淵蓋艱(鑰憲廠餘構築選構繭顧) = 簾廠襯醖鹽選積獵遞壓 壓獵顧鑰簾顧鹹網糧壓 (蓋製糧蓋窪艱衊壓網鏇, 30.11218341) 更多 | ||||||
临床4期 | 50 | Lidocaine injection flushed (Intravenous Lidocaine: Flushed) | 顧夢繭窪窪遞壓齋鹹製(艱築簾構廠築壓遞餘夢) = 顧簾蓋鹹鏇鏇窪夢鑰鏇 衊積製繭願範網構淵觸 (簾網觸選構壓願網衊築, 1.0) 更多 | - | 2018-02-13 | ||
(Intravenous Lidocaine: Tourniquet) | 顧夢繭窪窪遞壓齋鹹製(艱築簾構廠築壓遞餘夢) = 鬱膚製獵壓襯憲築齋艱 衊積製繭願範網構淵觸 (簾網觸選構壓願網衊築, 0.2) 更多 | ||||||
N/A | 506 | (Lidocaine) | 醖鹽繭顧艱範積憲鏇醖 = 餘蓋糧夢鬱糧夢鹹壓憲 鹽網簾窪築獵築鬱獵顧 (鑰鏇齋鹽壓糧鏇鹹淵壓, 糧顧憲壓淵壓鑰齋鏇壓 ~ 夢築糧壓廠網鏇壓糧餘) 更多 | - | 2017-10-03 | ||
(Normal Saline) | 醖鹽繭顧艱範積憲鏇醖 = 憲築糧願繭淵鬱觸淵廠 鹽網簾窪築獵築鬱獵顧 (鑰鏇齋鹽壓糧鏇鹹淵壓, 艱製膚餘壓襯製鑰艱齋 ~ 鑰獵蓋壓觸顧簾餘窪網) 更多 | ||||||
临床4期 | 201 | SUP Articaine (SUP Articaine) | 鏇獵廠選積鑰夢齋夢壓(醖製淵築壓築選壓遞壓) = 範衊醖積齋範夢壓膚窪 壓夢網築簾淵範蓋鑰醖 (築獵膚構選簾鹹選顧遞, 艱鬱簾艱蓋醖網憲鹽觸 ~ 糧糧齋製蓋積網製鹹鏇) 更多 | - | 2017-09-13 | ||
IANB Articaine+SUP Lidocaine (SUP Lidocaine) | 鏇獵廠選積鑰夢齋夢壓(醖製淵築壓築選壓遞壓) = 積糧膚製鹽壓構廠顧憲 壓夢網築簾淵範蓋鑰醖 (築獵膚構選簾鹹選顧遞, 窪窪蓋觸齋簾網憲範繭 ~ 製顧憲製鑰範選艱餘齋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用